OMDA · Nasdaq · Healthcare
Omada Health, Inc. (OMDA) — Rank #71 by gross profitability (GP/assets 0.52) · ROE -5.1% · Piotroski F-Score 6 / 9.
As-of 2026-10-30 · CIK 0001611115 · all metrics point-in-time as of the filing date.
About
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States.
Show moreShow less
The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners.
The company was incorporated in 2011 and is headquartered in South San Francisco, California.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- DE
- Filer Category
- Non-accelerated filerEmerging growth company
- Fiscal Year End
- December 31
- Website
- omadahealth.com
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
946
Industry
Health Information Services
Exchange
Nasdaq
11/12
Flags passed
OMDA passes 11/12 quality flags
1 caution to review
- CAUTIONDilution above 2%
Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation
- PASSGross margin holding
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSRevenue not declining
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths Revenue growth accelerating · Deferred revenue growing · Sequential beat (rev + EPS)
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passRevenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Does it make money well?
No warning flags · GP/assets 0.52
Gross profitability (GP / assets)
0.52
Primary signal (Novy-Marx).
3rd of 7 SIC 80 peers
Return on equity
-5.1%
Gross margin
65.7%
4th of 7 SIC 80 peers
Revenue growth (YoY)
53.2%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue vs COGS | |||
| Revenue vs OpEx | |||
| Op. Income vs Revenue |
Cash Flow Health
Is the cash real?
No warning flags · FCF 232% above net income
Free cash flow
$16.93M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
232.5%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
5.0%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
Caution: Dilution above 2% · net cash $221.71M, F-Score 6/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.30
1st of 6 SIC 80 peers (best = lowest)
Current ratio
3.91×
2nd of 7 SIC 80 peers
Quick ratio
3.69×
Net cash
$221.71M
Cash & equivalents minus total debt.
Piotroski F-Score
6 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Capital allocation quality
Composite score
2.0 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports